Staufen1 Interacts with Multiple Components of the Ebola Virus Ribonucleoprotein and Enhances Viral RNA Synthesis

Jingru Fang,a Colette Pietzsch,b,c Palaniappan Ramanathan,b,c Rodrigo I. Santos,b,c Philipp A. Ilinykh,b,c Mariano A. Garcia-Blanco,a,d Alexander Bukreyev,b,c,e Shelton S. Bradricka

aDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA
bDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA
cGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA
dProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
eDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas, USA

ABSTRACT Ebola virus (EBOV) genome and mRNAs contain long, structured regions that could hijack host RNA-binding proteins to facilitate infection. We performed RNA affinity chromatography coupled with mass spectrometry to identify host proteins that bind to EBOV RNAs and identified four high-confidence proviral host factors, including Staufen1 (STAU1), which specifically binds both 3’ and 5’ extracistronic regions of the EBOV genome. We confirmed that EBOV infection rate and production of infectious particles were significantly reduced in STAU1-depleted cells. STAU1 was recruited to sites of EBOV RNA synthesis upon infection and enhanced viral RNA synthesis. Furthermore, STAU1 interacts with EBOV nucleoprotein (NP), virion protein 30 (VP30), and VP35; the latter two bridge the viral polymerase to the NP-coated genome, forming the viral ribonucleoprotein (RNP) complex. Our data indicate that STAU1 plays a critical role in EBOV replication by coordinating interactions between the viral genome and RNA synthesis machinery.

IMPORTANCE Ebola virus (EBOV) is a negative-strand RNA virus with significant public health importance. Currently, no therapeutics are available for EBOV, which imposes an urgent need for a better understanding of EBOV biology. Here we dissected the virus-host interplay between EBOV and host RNA-binding proteins. We identified novel EBOV host factors, including Staufen1, which interacts with multiple viral factors and is required for efficient viral RNA synthesis.

KEYWORDS RNA binding proteins, RNA replication, ebola virus, virus-host interactions

Ebola virus (EBOV) has caused multiple human outbreaks, notably the 2013–2016 catastrophic epidemic in West Africa which led to more than 11,000 fatalities (1–3), and a new outbreak recently occurred in The Democratic Republic of the Congo (4). At present, no FDA-approved treatment is available for EBOV infections. Due in part to the high case fatality rate of up to 90% observed in infected patients, EBOV has been classified as a category A pathogen, posing a high risk to public health (5).

EBOV belongs to the family Filoviridae in the order Mononegavirales (6) and features a nonsegmented, negative-sense (NNS) RNA genome. The RNA genome is tightly encapsidated by viral nucleoprotein (NP) oligomers and closely associated with the viral RNA synthesis machinery, which is composed of the viral RNA-dependent RNA polymerase (L), the polymerase cofactor virion protein 35 (VP35), and the transcription activator VP30 (7). Together, they form a multiprotein-RNA complex, termed the viral ribonucleoprotein (RNP) complex (8). The NP-coated RNA genome serves as the template for synthesis of seven monocistronic, capped and polyadenylated mRNAs. In
addition, the genome is the template for synthesis of the replicative intermediate, or antigenome (9), which in turn serves as the template for synthesis of progeny genomes (10, 11). EBOV must have evolved a comprehensive strategy to regulate its RNA synthesis, coordinating viral mRNA transcription, genome replication, and viral RNP assembly; however, host factors participating in these processes are poorly understood.

The EBOV genome contains regions with predicted stable RNA structures (12). The genome contains terminal extracistronic regions, termed the 3’ leader and 5’ trailer, that are essential for RNA synthesis (13–15), and many of the viral transcripts have long untranslated regions (UTRs) (16). To some extent, the functional requirement of extracistronic regions for EBOV RNA synthesis has been documented by minigenome assays (17). For example, an important cis-acting RNA structure required for EBOV transcriptional regulation is located in the 3’ extracistronic region of the viral genome and functions through interaction with the viral trans-acting factor, VP30 (18–21). Nevertheless, functionality of most EBOV RNA secondary structures and potential host or viral trans-acting factors that recognize these structures have not been well established (22, 23).

Many RNA viruses induce the formation of discrete intracellular compartments that sequester viral RNA synthesis (24, 25). Previously published studies have implicated distinct EBOV-induced intracellular compartments, termed inclusion bodies (26), as the sites of EBOV RNA synthesis and generation of progeny viral RNPs (27–29). In contrast to viral proteins and RNA, few cellular factors, including several proteins implicated in translation such as eukaryotic initiation factor 4G (eIF4G), eIF3B, and poly(A)-binding protein, have been shown to localize to inclusion bodies. The functional outcome of redistribution of these cellular factors into EBOV inclusion body remains unclear (30).

While the EBOV genome is prominently coated with NP in infected cells, we posit that highly structured terminal regions of the genome may be available for interaction with other cellular and viral proteins, such as VP30. To identify host RNA-binding proteins (RBPs) that interact with the long and highly structured EBOV RNAs, we used RNA affinity chromatography combined with mass spectrometry (RAC-MS) and analyzed the functional effects of candidate EBOV RBPs on viral infection. We focused on Staufen1 (STAU1), which preferentially associates with both 3’ and 5’ extracistronic regions of EBOV genomic RNA, as an important EBOV proviral host factor. We demonstrated that STAU1 enhances EBOV RNA synthesis and that STAU1 is recruited to EBOV inclusion bodies during viral infection. Unexpectedly, we also revealed that endogenous STAU1 associates with multiple components of the EBOV RNP. Our observations suggest STAU1 is a cellular constituent of EBOV inclusion bodies that is actively engaged in the process of EBOV RNA synthesis.

RESULTS
Identification of cellular factors that bind to EBOV RNA and regulate viral infection. We hypothesized that certain EBOV RNAs predicted to form stable secondary structures could serve as cis-acting elements to hijack cellular factors that facilitate viral infection. To begin testing this hypothesis, we performed an RNA affinity chromatography combined with mass spectrometry (RAC-MS) screen to identify host proteins interacting with selected EBOV RNA regions (Fig. 1A). We chose a RAC method that has successfully been used to identify host RNA-binding proteins (RBPs) that bind to UTRs of dengue virus genomes and takes advantage of the tobramycin RNA aptamer that allows reversible coupling of RNA transcripts to a tobramycin affinity matrix (31–34). Previous work describing functional roles for EBOV 5’ UTRs in translational regulation was inspired by the fact that EBOV UTR sequences are, on average, longer than those of other nonsegmented, negative-sense RNA viruses (35). On the basis of a similar rationale, we selected the two longest EBOV mRNA 5’ UTRs that are predicted to have extensive RNA secondary structure (see Fig. S1 in the supplemental material): the 5’ UTR of NP mRNA (414 nucleotides [nt]) and the 5’ UTR of VP24 mRNA (460 nt). In addition, we analyzed the 5’ trailer of genomic RNA (676 nt), another long, structured extracistronic region. For comparison, the 5’ UTR of host mRNA from the DDX39B gene.
Identification of cellular factors that bind to EBOV RNA and regulate viral infection. (A) Workflow of RAC-MS and loss-of-function screening. Candidate cellular RBPs interacting with EBOV RNA were identified by two independent RAC-MS experiments. *In vitro*-transcribed EBOV 5’ trailer, NP mRNA 5’ UTR, and VP24 mRNA 5’ UTR were used as EBOV RNA baits; cellular DDX39B mRNA 5’ UTR was used as the reference RNA bait. Immobilized RNAs or matrix alone was incubated with HuH-7 cell lysate, and isolated proteins were analyzed by quantitative mass spectrometry. A total of 14 proteins identified as enriched for EBOV RNAs across two experiments were screened in infection assays. RNAi, RNA interference; dpi, days postinfection. (B) EBOV RBPs identified by RAC-MS. (Top) Total numbers of proteins identified in each experiment are shown in black. Numbers of proteins enriched two-fold or greater for any of the RNA baits compared to that for the matrix control are depicted in blue, and the number of proteins shared in the two experiments is shown in red. Exp, experiment. (Bottom) EBOV RBPs identified by RAC-MS. The 30 proteins common to both experiments were analyzed by two criteria in order to identify factors enriched for EBOV RNAs. Enrichment factor 1 is the abundance ratio for proteins binding the indicated EBOV RNA construct compared to the reference RNA. Enrichment factor 2 is defined as the abundance ratio for proteins binding the indicated EBOV RNA compared to the average for all RNA baits. Proteins with enrichment factor 1 or Perfect candidate EBOV RNA binding proteins identified in both Exp1 & Exp2.

Role of Staufen1 in Ebola Virus Infection

September/October 2018 Volume 9 Issue 5 e01771-18
mbio.asm.org

FIG 1 Identification of cellular factors that bind to EBOV RNA and regulate viral infection. (A) Workflow of RAC-MS and loss-of-function screening. Candidate cellular RBPs interacting with EBOV RNA were identified by two independent RAC-MS experiments. *In vitro*-transcribed EBOV 5’ trailer, NP mRNA 5’ UTR, and VP24 mRNA 5’ UTR were used as EBOV RNA baits; cellular DDX39B mRNA 5’ UTR was used as the reference RNA bait. Immobilized RNAs or matrix alone was incubated with HuH-7 cell lysate, and isolated proteins were analyzed by quantitative mass spectrometry. A total of 14 proteins identified as enriched for EBOV RNAs across two experiments were screened in infection assays. RNAi, RNA interference; dpi, days postinfection. (B) EBOV RBPs identified by RAC-MS. (Top) Total numbers of proteins identified in each experiment are shown in black. Numbers of proteins enriched two-fold or greater for any of the RNA baits compared to that for the matrix control are depicted in blue, and the number of proteins shared in the two experiments is shown in red. Exp, experiment. (Bottom) EBOV RBPs identified by RAC-MS. The 30 proteins common to both experiments were analyzed by two criteria in order to identify factors enriched for EBOV RNAs. Enrichment factor 1 is the abundance ratio for proteins binding the indicated EBOV RNA construct compared to the reference RNA. Enrichment factor 2 is defined as the abundance ratio for proteins binding the indicated EBOV RNA compared to the average for all RNA baits. Proteins with enrichment factor 1 or

(Continued on next page)
(502 nt) was chosen as reference RNA. Human HuH-7 hepatoma cell lysate was used for identification of EBOV RNA-binding proteins, as liver is one of the main target organs of EBOV (36). Proteins identified across two independent experiments are shown in Data Set S1 in the supplemental material.

We used multiple criteria to classify proteins identified by quantitative MS. The first criterion excluded proteins that nonspecifically bound to the matrix. After ruling out nonspecific interactors, we identified 30 host RBPs shared in both experiments (Fig. 1B).

We then classified proteins that bound to one or more EBOV RNAs with higher abundance (twofold or more) than to the DDX39B 5′ UTR. This identified 14 factors that were consistently enriched in both experiments as candidate EBOV RBPs (Fig. 1B and Fig. S2). As expected, the majority of these proteins have been previously reported as RBPs (37–44). Interleukin enhancer-binding factor 2 (ILF2), interleukin enhancer-binding factor 3 (ILF3), DExH-box helicase 9 (DHX9), RNA binding motif single-stranded interacting protein 1 (RBMS1), zinc finger protein 346 (ZNF346), Staufen double-stranded RNA-binding protein 1 (Staufen1 [STAU1]), and tripartite motif containing 71 (TRIM71) demonstrated selective binding to the 5′ trailer of EBOV genomic RNA. On the other hand, insulin-like growth factor 2 mRNA-binding proteins 1 and 3 (IGF2BP1 and IGF2BP3) demonstrated selective binding to both EBOV 5′ UTRs (Fig. 1B and Fig. S2).

We next asked whether the 14 hits identified by RAC-MS affect EBOV infection of HuH-7 cells. We performed small interfering RNA (siRNA)-mediated depletion of each target protein, followed by infection with a replication-competent recombinant EBOV expressing enhanced green fluorescent protein (eGFP) (EBOV-eGFP) (45), and measured the percentages of cells infected. Cells were transfected with either a nonsilencing control siRNA (NSC) or three independent siRNAs (S1/2/3) targeting the mRNA for each of the selected proteins and infected with EBOV-eGFP at a multiplicity of infection (MOI) of 1 PFU per cell. In general, the majority of siRNAs tested resulted in decreases in the rate of infection. Among the 14 hits, depletion of ILF2, ILF3, heterogeneous nuclear ribonucleoprotein L (HNRNPL), and STAU1 significantly decreased EBOV-eGFP infection for each siRNA used (Fig. 1C). For ILF2, ILF3, and HNRNPL, some siRNAs moderately reduced cell numbers, reflecting lower cell proliferation or a degree of toxicity that may influence EBOV infection (Fig. S3). In contrast, none of the three siRNAs targeting STAU1 reduced cell numbers. Together, these data suggest that these four proteins represent host factors required for efficient replication of EBOV in HuH-7 cells.

**STAU1 is an EBOV proviral host factor that binds to both 3′ and 5′ extracistronic regions of the EBOV genome.** We next focused on the role of the double-stranded RNA-binding protein STAU1, because it has not been previously implicated as an EBOV host factor, but it has been reported to play important roles for other RNA viruses (46–48). First, we sought to validate the interaction between STAU1 and EBOV RNA. We repeated RAC assays and detected STAU1 by Western blotting. In addition to the 5′ trailer RNA used for RAC-MS, we also analyzed RNAs encompassing the 3′ extracistronic region of the EBOV genome with the 55-nt 3′ leader sequence ΔLe(1-469) or without the 55-nt 3′ leader sequence ΔLe(56-469) (Fig. 2A and B). Both the 3′ extracistronic region and 5′ trailer of EBOV contain essential signals required for EBOV RNA synthesis (13). We observed that endogenous STAU1 bound the EBOV 5′ trailer RNA more strongly than the 5′ UTR of NP mRNA, validating the RAC-MS data. Interestingly, in addition to the EBOV 5′ trailer, we also found that STAU1 bound to the EBOV 3′ trailer.
3’ extracistronic region (positions 56 to 469) independently of the 55-nt leader sequence (Fig. 2B). To extend these observations, we performed RNA immunoprecipitation (IP) from 293T cells transiently expressing EBOV minigenome RNA (see below) with or without overexpression of Flag-tagged STAU1 (STAU1-Flag). IP was performed, and RNA coprecipitating with STAU1-Flag or negative-control beads was subjected to reverse transcription-quantitative PCR (RT-qPCR) for measurements of EBOV minigenome RNA and 18S rRNA. This analysis revealed that STAU1-Flag IP enriched EBOV minigenome RNA by approximately sixfold compared to the negative control, whereas 18S rRNA levels were similar for both (Fig. S4). Together, these data indicate that STAU1 preferentially interacts with the terminal extracistronic regions of the EBOV genome in vitro.

FIG 2  STAU1 is an EBOV proviral host factor and binds to 3’ and 5’ extracistronic regions of the viral genome. (A) Schematic of EBOV RNAs used in RAC for Western blot (WB) analysis. In vitro-transcribed EBOV NP 5’ UTR, 3’ extracistronic region [Le(1-469)], truncated 3’ extracistronic region [ΔLe(56-469)], and 5’ trailer (Tr) were used as RNA baits in RAC-WB experiments with HuH-7 cell lysate. Matrix alone served as a negative control. (B) Selective association of the 3’ and 5’ extracistronic regions of the EBOV genome with endogenous STAU1. Proteins pulled down were analyzed by WB performed with anti-STAU1 antibody. A representative blot is shown. Quantitation of bands corresponding to STAU1 from two independent experiments is shown (range and mean values, with the value for matrix normalized to 1). (C) Effect of STAU1 knockdown on EBOV growth kinetics. HuH-7 cells were transfected with STAU1 or nonsilencing control (NSC) siRNAs 48 h prior to infection with EBOV-eGFP at an MOI of 3 PFU per cell (one-step growth kinetics) or at an MOI of 0.01 PFU per cell (multistep growth kinetics). Supernatants were collected at the indicated time points, and infectious particle production was determined by plaque assay. B.D., below detection. Values are means ± standard errors of the means (error bars). Values that are significantly different by unpaired, two-tailed t test are indicated by asterisks as follows: *, P < 0.05; ***, P < 0.0005. (D) Western blot demonstrating kinetics of STAU1 knockdown in HuH-7 cells corresponding to indicated time points in EBOV growth kinetics.
To confirm the importance of STAU1 for EBOV infection, we characterized the growth kinetics of EBOV-eGFP in STAU1-depleted HuH-7 cells in both one-step (MOI of 3 PFU per cell) and multistep (MOI of 0.01 PFU per cell) infection assays. We performed siRNA-mediated depletion of STAU1 in HuH-7 cells, followed by infection of EBOV-eGFP, and determined the yield of infectious particles secreted into cell supernatants by plaque assay. We also analyzed the kinetics of STAU1 depletion by individual siRNAs. For the one-step growth curve experiment, the yield of infectious particles in STAU1-depleted cells was significantly lower at days 1 and 2 postinfection than in cells transfected with NSC siRNA, indicating that STAU1 knockdown significantly slows the kinetics of EBOV infection (Fig. 2C). For the multistep growth curve experiment, most siRNA/time point combinations showed reduced yield of infectious particles in STAU1-depleted cells on days 2 to 5 postinfection (Fig. 2C). Furthermore, two STAU1 siRNAs (s1 and s3) showed stronger STAU1 depletion, and this was correlated with larger effects on the yield of infectious virus compared to the s2 siRNA (Fig. 2D). In summary, these data show that STAU1 promotes efficient infection of HuH-7 cells by EBOV.

**STAU1 is recruited to EBOV inclusion bodies.** Given that STAU1 was identified as a putative EBOV RBP, we hypothesized that it may be in close proximity to EBOV inclusion bodies where EBOV RNA synthesis takes place (27). To determine whether STAU1 is recruited to EBOV inclusion bodies upon viral infection, we performed a time course infection and visualized localization of endogenous STAU1 by immunofluorescence analysis (IFA). It has been previously shown that EBOV VP35 functions as a component of viral RNA synthesis machinery (49) and localizes to EBOV inclusion bodies (28). Therefore, we used it as a marker for EBOV inclusion bodies in infected cells. In mock-infected HuH-7 cells, STAU1 was observed to localize diffusely in the cytoplasm, which is consistent with previous reports describing STAU1 localization to the rough endoplasmic reticulum (Fig. 3A) (50). At 6 h postinfection (hpi), only a minority of cells had VP35 signal, which was distributed in an amorphous fashion, while the overall organization of STAU1 did not show any significant change in pattern. At 18 hpi, changes in STAU1 localization started to become apparent: small spherical EBOV inclusion bodies started to form in the cytosol in a few cells, and a portion of endogenous STAU1 colocalized with these EBOV inclusion bodies. At 24 hpi, most cells were VP35 positive with sizable EBOV inclusion bodies that colocalized with STAU1 in most cells (Fig. 3A). We further analyzed STAU1-VP35 colocalization in HuH-7 cells at 24 hpi by line profile analysis and found highly correlated distribution of STAU1 and VP35 signals (Fig. 3B).

We next sought to determine whether STAU1 is important for the formation of EBOV inclusion bodies. Analysis of the quantity of EBOV inclusion bodies revealed no differences in STAU1-depleted cells compared to control cells (Fig. S5A and B), suggesting that STAU1 is dispensable for EBOV inclusion body formation. Despite this, our results showed that endogenous STAU1 still colocalized with EBOV inclusion bodies when its protein level was significantly depleted. These observations suggest a possible role for STAU1 in EBOV RNA synthesis that is thought to take place exclusively within inclusion bodies.

**STAU1 promotes EBOV RNA synthesis.** We next asked whether STAU1 facilitates viral RNA synthesis. To quantify EBOV RNA synthesis independently from other steps of the viral life cycle, we used a previously established EBOV minigenome system that recapitulates genome transcription, replication, and encapsidation (13) (Fig. 4A). We opted to use 293T cells for these experiments, since we were unable to detect minigenome activity in transfected HuH-7 cells (unpublished data). In the EBOV minigenome plasmid, the entire coding sequence is replaced by a firefly luciferase (Fluc) reporter gene that is flanked by *bona fide* 3’ and 5’ extracistronic regions of the EBOV genome required for EBOV RNA synthesis. Viral proteins (NP, VP35, VP30, and L) are supplied by cotransfection of expression plasmids, and a *Renilla* luciferase (Rluc) expression plasmid is included to normalize for transfection efficiency. The resulting Fluc signal normalized against control Rluc signal is taken as a measure of the activity
of EBOV RNA synthesis, which reflects a combination of both genome replication and transcription. We depleted or overexpressed STAU1 in 293T cells and transfected the minigenome system plasmids 48 h later. We observed that cells overexpressing STAU1 (Fig. 4B) showed significantly enhanced EBOV minigenome activity compared to control cells (Fig. 4C, left panel). On the other hand, in STAU1-depleted cells (Fig. 4B), the EBOV minigenome activity was significantly decreased compared to the negative control (Fig. 4C, right panel). Together, these results indicate that STAU1 is required for efficient EBOV RNA synthesis.

**STAU1 interacts with major components of the EBOV RNP.** To further understand the mechanism by which STAU1 enhances EBOV infection, we probed for physical interactions between STAU1 and isolated components of the EBOV RNP. Specifically, we asked whether STAU1 could interact directly or indirectly with VP35 and/or NP in the absence of active virus infection using coimmunoprecipitation (co-IP) assays. 293T cells were cotransfected with plasmids expressing recombinant Flag-tagged STAU1 and either hemagglutinin (HA)-tagged VP35 (HA-VP35) (Fig. 5A, lane 4) or NP (Fig. 5A, lane 5). In addition, cells transfected with plasmids expressing either Flag-STAU1, HA-VP35, or NP alone served as controls (Fig. 5A, lanes 1 to 3). Forty-eight hours posttransfection, anti-Flag IPs were performed using whole-cell lysate in the presence or absence of RNase A/T1 treatment. VP35 and NP were found to co-IP with STAU1 under both conditions, suggesting that the interactions are not bridged by RNA

---

** FIG 3 ** STAU1 is recruited to viral inclusion bodies upon EBOV infection. (A) HuH-7 cells were transfected with nonsilencing control siRNA 48 h prior to infection with EBOV at an MOI of 3 PFU per cell. Cells were fixed at 6, 18, and 24 h postinfection and immunostained with anti-STAU1 antibodies (red) and anti-EBOV VP35 antibodies (green) for confocal microscopy. Nuclei were visualized by Hoechst staining. Representative fields are shown from two independent experiments with duplicate wells. Bars = 20 μm. (B) Colocalization analysis of endogenous STAU1- and VP35-containing EBOV at 24 h postinfection (MOI of 3 PFU per cell) was conducted along the white segmented line for each channel. The line profile plot of the fluorescence intensity (in arbitrary units [AU]) of STAU1 and EBOV VP35 in the same focal plane is shown.
In the same experiment, cells were cotransfected with plasmids expressing all three proteins (Fig. 5A, lane 6), and STAU1 was found to similarly co-IP both VP35 and NP (Fig. 5A, lanes 12 and 18). Notably, we used a particular NP/VP35 ratio (1:0.25) in transfections based on the results of a previous experiment (Fig. 5A, lanes 10, 11, 16, and 17). In the same experiment, cells were cotransfected with plasmids expressing all three proteins (Fig. 5A, lane 6), and STAU1 was found to similarly co-IP both VP35 and NP (Fig. 5A, lanes 12 and 18). Notably, we used a particular NP/VP35 ratio (1:0.25) in transfections based on the results of a previous experiment.
study which found that a high level of VP35 interferes with EBOV nucleocapsid formation in a VP35/NP overexpression system (S1).

Due to the relatively low signal of VP35 in STAU1 Flag IP samples, we performed a reverse co-IP to confirm the interaction between these proteins. 293T cells were transfected with a plasmid expressing HA-VP35, and anti-HA IPs were performed in the presence or absence of RNase treatment. We observed endogenous STAU1 to co-IP with HA-VP35 (Fig. 5B). Additional co-IP experiments to map the interaction between STAU1 and VP35 suggested that both the C-terminal domain (containing amino acids 1 to 218) and the N-terminal domain (containing amino acids 219 to 340) of VP35 protein contribute to its interactions with STAU1 (Fig. S6A). In addition, we found that STAU1 coprecipitates with the EBOV VP30 transcription factor (Fig. S6B) in an RNA-independent manner, further supporting a role for STAU1 in EBOV RNA synthesis.

We also probed for two cellular proteins that have been previously linked to VP35 and/or STAU1. In contrast to a previous study (S2), we did not observe G3BP stress granule assembly factor 1 (G3BP1) to co-IP with VP35 (Fig. 5B). In contrast, we observed HA-VP35 to co-IP the eukaryotic initiation factor 2 (eIF2α) kinase 2 (EIF2AK2)/protein kinase R (PKR), which has previously been reported to interact with STAU1 (46) and be inhibited by VP35 (S3, S4). We also observed PKR to co-IP with VP30 in an RNA-independent manner (Fig. S6B).

Together, our results show that STAU1 is able to interact with both VP35 and NP. Although each of these three proteins is capable of RNA binding, co-IP was resistant to RNase treatment, suggesting that RNA was not required for the interaction. Importantly, associations between STAU1 and either VP35 or NP were not altered when both proteins are coexpressed, which has been shown to result in formation of NP/VP35 helical structures that contain cellular RNA and resemble viral nucelocapsids (S1). This result implies that STAU1 interaction with VP35 is not competed by NP and vice versa. Thus, we posit that these proteins can form a trimeric complex in cells.

We further investigated the potential for colocalization of endogenous STAU1 and EBOV VP35/NP by immunofluorescence analysis. Specifically, we asked whether expression of NP, VP35, or both proteins is sufficient to recruit endogenous STAU1 to cytosolic granular structures formed by these proteins. First, consistent with previous studies (S1, S5, S6), we found that transient NP expression alone was able to induce cytoplasmic inclusion bodies in HuH-7 cells (Fig. 6, NP-Flag only). Second, endogenous STAU1 was recruited to NP-induced cytoplasmic inclusion bodies (Fig. 6, NP-Flag only), consistent with our previous observation showing that, in EBOV-infected cells, endogenous STAU1 is localized in viral inclusion bodies containing VP35 (Fig. 3). In contrast to NP, we found that transient VP35 expression alone did not form structures reminiscent of NP-induced inclusion bodies but localized in smaller, more diffuse aggregates. However, endogenous STAU1 was still recruited to VP35 aggregates (Fig. 6, VP35 only). Finally, we found that coexpression of NP and VP35 led to formation of NP-induced inclusion bodies, which also contained STAU1 (Fig. 6, VP35 plus NP-Flag). Together with co-IP data shown in Fig. 5, these data suggest that EBOV VP35-NP complex recruits host STAU1 into cytoplasmic inclusion bodies that resemble EBOV inclusion bodies.

**STAU1 and EBOV NP/VP35/genomic RNA cofractionate in a density gradient.**

Our results imply a possible ternary complex between STAU1, NP, and VP35 proteins. In addition, on the basis of our RAC data, we hypothesized that EBOV minigenome RNA, which harbors 3’ and 5’ extracistronic regions of the EBOV genome, would cofractionate with STAU1 together with NP and VP35 in sucrose density gradient centrifugation. To investigate the possibility that STAU1 can form a complex with EBOV RNP components, we cotransfected 293T cells with plasmids expressing EBOV NP, VP35, and the T7 promoter-driven EBOV minigenome with or without T7 polymerase expression plasmid.

After 48 h, cytoplasmic lysates were harvested and separated on 20 to 60% sucrose density gradients. We fractionated the gradients and analyzed the distribution of target proteins and RNA in gradient fractions.

Consistent with our previous findings, STAU1 primarily cosedimented with NP and VP35 in low-density fractions (Fig. 7A and Fig. S7A, fractions 1 to 8), but cosedimen-
tation was also evident in the high-density fractions in the absence of EBOV minigenome RNA (Fig. 7A and Fig. S7A, fraction 21). In a repeat experiment, we also found PKR cosedimented with STAU1, NP, and VP35 in low-density fractions, both with and without EBOV minigenome RNA (Fig. S7). Importantly, we observed that expression of EBOV minigenome RNA led to a faster-migrating complex containing STAU1, NP, VP35, and EBOV minigenome RNA (Fig. 7B, fraction 23). In a repeat experiment, we observed a similar shift in STAU1/NP/VP35 due to expression of EBOV minigenome RNA (Fig. S7A and B). This result suggests that STAU1 is capable of forming an RNP complex with EBOV genomic RNA, NP, and VP35 proteins in cells (Fig. S8).

DISCUSSION

Our data provide evidence that STAU1 is the first cellular factor reported to associate with three essential components of the EBOV RNA synthesis machinery: NP, VP35, and VP30. The NP-VP35 complex serves as a critical backbone for the viral polymerase L to
recognize NP-encapsidated RNA genomes, which is the prerequisite for both EBOV transcription and genome replication. Similarly, VP30 is also believed to bridge interactions between L and NP, and it is critical for transcription of viral mRNA (13, 57). Our observations further imply an association of STAU1 with the EBOV RNA genome-NP-VP35 complex, suggesting that regions of the EBOV genome are available for interaction with trans-acting factors in the presence of NP. Related to our finding that STAU1 preferentially binds to 3' and 5' extracistronic regions of the EBOV genome in vitro, we propose a model in which STAU1 is involved in the early formation of EBOV RNA synthesis machinery on the 3' extracistronic region of the EBOV genome, and likewise, in the termination and release of EBOV RNA synthesis machinery on the 5' extracistronic region (see Fig. S8 in the supplemental material).

Previous efforts have been made to understand EBOV host factor biology by
focusing on protein-protein interactions between viral and host proteins (58–62). To provide more insights into how host factors regulate EBOV replication through cis-acting elements in EBOV RNA, we performed a RAC-MS screen and discovered 14 host RBPs specifically enriched for the selected EBOV noncoding RNAs. Among these RBPs, ILF2, ILF3, HNRNPL, and STAU1 stand out as strong EBOV candidate host factors because all three siRNAs tested caused a significant reduction of EBOV infection. While HNRNPL preferentially associated with the 5′ UTR of EBOV NP mRNA, ILF2, ILF3, and STAU1 selectively interacted with the EBOV trailer. It is noteworthy that ILF3 (also known as DRBP76/NF90) was previously identified as a VP35 interactor as well as an EBOV polymerase suppressor (61). Although this previous study did not observe a dramatic effect of reduced ILF3 expression on EBOV infection in 293T cells, the data we present here showed that depletion of ILF3 in HuH-7 cells significantly impaired EBOV infection. This discrepancy could be explained by cell line differences. Nevertheless, the identification of ILF2 (or NF45) in our screen, which is physically and functionally linked to ILF3 (44), highlights the important role that ILF3 perhaps has in EBOV infection.

We focused on STAU1 as a novel EBOV host factor that promotes efficient virus infection. STAU1 is a protein that binds to stable RNA secondary structure (63), a tubulin-binding protein that interacts with cytoskeleton (50), a ribosome-associated protein (64, 65) that accumulates in stress granules induced by certain types of stress (66), and a key mediator of mRNA decay (67, 68). These biochemical characteristics enable STAU1 to fulfill different biological functions: from controlling the localization to enhancing the translation of its target RNAs. Therefore, elucidation of a functional domain(s) of STAU1 that is responsible for EBOV host factor activity may allow generation of targeted inhibitors antagonizing the STAU1 proviral effect.

Previous studies of several RNA viruses have revealed that STAU1 binding to viral RNA regulates infection. For instance, STAU1 facilitates translation of hepatitis C virus RNA through binding to the internal ribosome entry site (46). STAU1 plays a role in the production of viral particles for both influenza A virus (47) and human immunodeficiency virus type 1 (48). Our RAC-MS results indicated that STAU1 preferentially associates with EBOV genomic RNA and not with the 5′ UTR of two viral mRNAs. Therefore, it is unlikely that STAU1 promotes EBOV mRNA translation; however, we tested only the 5′ UTRs of NP and VP24 transcripts, so we cannot eliminate the possibility that STAU1 may bind to other UTRs and participate in their translation. Another caveat is that the EBOV genomic RNA used in the RAC experiment was naked, while during infection, it is likely to be mostly encapsidated by NP and therefore relatively inaccessible (69). Nevertheless, the facts that STAU1 is recruited to sites of viral RNA synthesis and forms a complex in cells with NP, VP35, and minigenome RNA suggest interactions between STAU1 and EBOV genomic RNA in infected cells.

Several other stress granule (SG) markers (for instance, the initiation factors eIF3 and eIF4G) were previously found to localize on discrete, compact granules within EBOV inclusion bodies (30). In contrast to this, STAU1 in EBOV inclusion bodies appeared in a heterogeneous pattern that changed over the course of infection. In some areas near the border of EBOV inclusion bodies, where VP35 was almost absent, STAU1 formed small aggregates that branched out of the inclusion border (Fig. S5C). This distinct distribution of STAU1 suggests that it may function differently than other SG proteins with regard to interactions with EBOV inclusion bodies.

Given the correlation between the level of STAU1 expression and EBOV minigenome activity, it is of interest to pinpoint the molecular event(s) STAU1 regulates during EBOV RNA synthesis. For nonsegmented, negative-sense RNA viruses, the first step of viral RNA synthesis is primary transcription in order to generate sufficient levels of viral proteins. When a supply of NP has been synthesized, genome replication and secondary transcription are allowed to commence, leading to the production of encapsidated antigenomes and progeny genomes as well as naked mRNAs (70). Attempts to distinguish whether STAU1 enhances genome replication or transcription using the minigenome system by strand-specific quantitative PCR (qPCR) were not successful, however, due to residual DNA from transfected plasmids despite DNase treatment of RNA
samples. Future studies using other model systems (i.e., replication-deficient mini-genome) are required to ascertain whether STAU1 participates in EBOV transcription (71).

Preliminary characterization of STAU1-associated EBOV minigenome RNP (reconstituted by EBOV minigenome RNA, NP, and VP35) revealed another interesting cellular player, PKR. Although PKR is well-known for its antiviral function by sensing viral RNA and phosphorylating the host translation initiation factor eIF2α (72), it has also been implicated in the phosphorylation and regulation of the HIV trans-acting protein Tat, which binds to the transactivation-responsive element (TAR) in the HIV genome, in the context of viral infection (73, 74). Interestingly, no host kinase has yet been reported to regulate phosphorylation of EBOV VP30, even though a growing number of studies indicate a crucial role of dynamic VP30 phosphorylation in EBOV RNA synthesis and RNP assembly (19, 21, 55, 75, 76). Although several reports indicate that EBOV antagonizes PKR activity (53, 54), one can imagine scenarios in which PKR is hijacked by this STAU1-containing viral RNP complex to dynamically control the phosphorylation of EBOV VP30. Further investigation is needed to clarify the role of PKR in EBOV infection.

In conclusion, we identified STAU1 as the first host factor reported to interact with multiple EBOV RNP components, highlighting the significance of this RBP for the EBOV life cycle. These interactions together with redistribution of STAU1 to EBOV inclusion bodies and to NP-induced inclusion bodies link STAU1 to EBOV RNA synthesis, for which we speculate that STAU1 facilitates both the initiation and termination steps. It will be of interest to clarify the exact molecular events occurring during initiation and termination of EBOV RNA synthesis and how STAU1 may participate in these processes. Our study contributes to knowledge of the role of host factors in EBOV RNA synthesis and provides a novel cellular target for the development of possible therapeutic interventions to combat EBOV infection.

MATERIALS AND METHODS

Cell lines and viruses. HuH-7 and 293T cells were maintained in Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), streptomycin (100 µg/ml), nonessential amino acids, and plasmocin (2.5 µg/ml). Vero-E6 cells were maintained in minimum essential medium supplemented with 10% FBS, 1% sodium pyruvate, and 0.1% gentamicin sulfate. All cells were grown at 37°C and 5% CO2. EBOV strain Mayinga and Mayinga expressing green fluorescent protein (GFP) were kindly provided by Yoshihiro Kawaoka (University of Wisconsin). The EBOV minigenome system was kindly provided by Elke Mühlberger (Boston University). The pcDNA5-eVP35-HA plasmid and deletion variants were constructed by introducing a C-terminal hemagglutinin (HA) epitope tag by PCR amplification and cloning into pcDNA5/FRT/TO using KpnI and NotI. The pRL-TK plasmid was purchased from Promega. The pcAGGS-eN-FLAG plasmid was a gift from Daniel Engel (University of Virginia).

Antibodies. Antibodies 6C5, 45, and 49 were purchased from Kerafast. Anti-NP antibody was purchased from IBT Bioservices. Anti-STAU1 (EPR7966) and anti-HA tag (16B12) antibodies were purchased from Abcam. Antitubulin antibody (B-5-1-2) was purchased from Invitrogen. All small interfering RNAs (siRNAs) were purchased from Qiagen (see Table S1 in the supplemental material), including the AllStars negative control siRNA. Band intensity quantification for Western blots was performed using Image Studio version 5.2 (LI-COR).

Identification of EBOV RBPs by RAC-MS. RNA affinity chromatography combined with mass spectrometry (RAC-MS) experiments were performed as described previously (77). Briefly, HuH-7 cytoplasmic lysate containing 5 mg of total protein was used for each binding reaction mixture with 25 pmol of noncapped, in vitro-transcribed RNA immobilized on tobramycin-coupled N-hydroxysuccinimide (NHS)-activated Sepharose matrices. Eluted proteins were subjected to either quantitative mass spectrometry or Western blot analysis. For proteins identified by MS, the abundance of each protein is indicated by normalized total spectral counts. We calculated the average abundance of identified proteins in eluate from each RNA construct and normalized it to that from the matrix, which we termed RNA/matrix ratio. From duplicate RAC-MS experiments, we classified host RNA-binding proteins (RBPs) in each sample as proteins with RNA/matrix ratios of >2. To identify RBPs preferentially bound to EBOV RNA, we introduced two enrichment factor criteria to exclude proteins bound nonspecifically to all RNAs. We defined enrichment factor 1 as the ratio of the protein abundance in eluate from a particular EBOV RNA to that from the DDX39B reference RNA. Similarly, we defined enrichment factor 2 as the ratio of...
the protein abundance in eluate from a particular EBOV RNA to the mean of all RNAs tested. Proteins specifically bound to EBOV RNA were selected with at least one enrichment factor larger than 2.

**siRNA screening.** HuH-7 cells (6 × 10⁶) were transfected the next day with siRNA using Lipofectamine RNAiMAX. Cells were transfected the next day with 10 μl siRNA using Lipofectamine RNAiMAX. Cells were transferred to BSL-4 and 48 h later were infected with EBOV expressing enhanced GFP (EBOV-eGFP) at an MOI of 1 PFU per cell. At 72 h postinfection (hpi), the cells were fixed with formalin and removed from BSL-4 conditions. Nuclei were visualized by Hoechst staining. Rates of infected cells were determined by measuring GFP-positive cells using an Opera Phenix high-content imager. Representative images of fixed and stained monolayers were taken using a wide-field fluorescence microscope (Olympus).

**EBOV growth kinetics.** HuH-7 cells (3 × 10⁶) were seeded in 24-well plates and transfected with siRNA the next day as described above. Twenty-four hours later, cells were maintained under BSL-2 conditions for Western blot analysis or transferred into BSL-4 facilities for infection. Forty-eight hours after transfection, cells were infected with EBOV-eGFP at an MOI of 3 or 0.01 for 1 h. Infection of the cells was followed by removal of the inoculum, washing the cells with phosphate-buffered saline (PBS) three times, and adding fresh medium containing 2% FBS to the cells. Aliquots of supernatant were harvested every 24 h for virus titration.

**EBOV minigenome assay.** 293T cells (3 × 10⁶) were seeded in 24-well plates and transfected the next day with siRNA at a final concentration of 10 nM per well using Lipofectamine RNAiMAX 48 h prior to minigenome transfection. For STAU1 overexpression, 6 × 10⁶ 293T cells were seeded in 24-well plates and transfected the next day with 500 ng of pCI-neo-STAU155R-FLAG or 500 ng of a control pCI plasmid using Lipofectamine 2000 24 h prior to minigenome transfection. Experiments involving the EBOV minigenome were performed essentially as previously described (19). Confuent monolayers were transfected with the following plasmids: 50 ng pCEZ-NP, 50 ng pCEZ-VP35, 30 ng pCEZ-VP30, 400 ng pCEZ-L, 100 ng pCAGGS-T7, 100 ng EBOV minigenome, and 4 ng pRL-TK. A control was included in every assay in which the pCEZ-L plasmid was omitted to verify active RNA synthesis. Plasmids were transfected with TransIT-LT1 transfection reagent (3 μl/μg plasmid). At 48 h posttransfection, cells were lysed and subjected to the dual-luciferase reporter assay (Promega). Knockdown of STAU1 was consistent between the time of minigenome plasmid transfection (Fig. 4B) and harvesting of lysates for luciferase assay (unpublished data).

**Immunoprecipitation and RNA-IP.** 293T cells (6 × 10⁶) seeded in 100-mm dishes were transfected the next day with 14 μg total plasmid(s) using Lipofectamine 2000. Forty-eight hours posttransfection, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors. Anti-HA or anti-Flag M2 agarose beads were blocked in NT2 buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM MgCl₂, and 0.05% NP-40) with bovine serum albumin (BSA) (0.5 mg/ml) for 30 min. One milligram of cell lysate with or without RNase treatment (0.4 U/ml RNase A and 16.6 U/ml RNase T1, 37°C, 15 min; verified to degrade total RNA in 1 mg of 293T lysate) was added to agarose beads and incubated overnight at 4°C with rotation. After four washes with NT2 buffer, proteins were eluted in sample buffer and analyzed by Western blotting. In RNA immunoprecipitation (RNA-IP) experiments, RNA was eluted from IP reaction mixtures using TRIzol-LS and analyzed by reverse transcription-quantitative PCR (RT-qPCR) using primers that specifically recognize EBOV trailer.

**Immunofluorescence analysis (IFA).** HuH-7 cells grown on 8-well chamber slides were fixed with 4% paraformaldehyde (PFA) for 15 mins, permeabilized with 0.5% Triton X-100 for 10 min, and incubated in blocking solution (1% normal goat serum in PBS) for 1 h at room temperature (RT). Primary antibodies were incubated for 2 h at RT or overnight at 4°C. After the cells were washed with PBST (PBS containing 0.1% Tween 20), secondary antibodies and Hoechst stain were added, and cells were incubated for 1 h at RT followed by washes with PBST. Monolayers were fixed with formalin and removed from BSL-4 following SOP. To neutralize formalin, monolayers were treated with 0.1 M glycine for 10 min at room temperature, mounted in ProLong Gold antifade reagent and analyzed by laser scanning confocal microscopy using an Olympus FV1000 confocal microscope with a 60× immersion oil lens. The number and area of EBOV inclusion bodies were quantified using Image J software.

**IF of cells expressing EBOV proteins.** HuH-7 cells (3 × 10⁶) grown on six-well glass bottom plates were transfected with a total of 2.5 μg of plasmid(s) in different combinations: NP-flag only, VP35 only, and NP-flag and VP35 (4:1). At 24 h posttransfection, cells were fixed, permeabilized, and incubated with different combinations of antibodies. After the final wash with PBST, cells were mounted and analyzed by wide-field fluorescence microscopy (Olympus) using an Olympus IX71 microscope with a 60× immersion oil lens.

**Sucrose density gradient analysis.** Cell fractionation on sucrose gradients was adapted from previous studies (48, 65). 293T cells (1.6 × 10⁷) grown in 100-mm dishes were transfected with plasmids expressing EBOV NP (5.6 μg), VP35 (1.4 μg), and T7 polymerase (3.5 μg) with or without the T7 promoter-driven EBOV minigenome plasmid (3.5 μg). After 48 h, cells were harvested and homogenized in 2 ml lysis buffer (10 mM HEPES [pH 7.5], 12.5% sucrose, 1 mM EDTA, 1 μM protease inhibitor). Sequential centrifugations at 300,000 × g were performed, and the resulting supernatants were layered onto a sucrose gradient consisting of 20 to 60% sucrose gradients in 10 mM HEPES (pH 7.5) and 1 mM MgCl₂, and centrifuged at 300,000 × g for 2.5 h in a SW40 rotor (Beckman). Fractions were collected from top to bottom, and protein and RNA were collected from each fraction for quantification by Western blotting and RT-qPCR, respectively.

**Statistical analysis.** Details regarding number of replicates and type of statistical test can be found in figure legends. Statistical analyses were performed using GraphPad Prism version 5.01.
SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at https://doi.org/10.1128/mBio.01771-18.

DATA SET S1, XLSX file, 0.02 MB.
FIG S1, TIF file, 15.4 MB.
FIG S2, TIF file, 25.9 MB.
FIG S3, TIF file, 14.9 MB.
FIG S4, TIF file, 9.3 MB.
FIG S5, TIF file, 89.1 MB.
FIG S6, TIF file, 48.4 MB.
FIG S7, TIF file, 89.3 MB.
FIG S8, TIF file, 0.3 MB.

TABLE S1, DOCX file, 0.01 MB.

ACKNOWLEDGMENTS

We thank Jonathan Towner (CDC) and Stuart Nichol (CDC) for providing the EBOV full-length clone, Yoshihiro Kawaoka (University of Wisconsin) for providing the EBOV NP, VP35, L, VP30, and T7 polymerase plasmids, Elke Mühlberger (Boston University) for providing the EBOV minigenome, Lynne Maquat (University of Rochester) for providing the pCI-neo-STAU155R-FLAG WT expression plasmid, and Miyake Tsuyoshi from the laboratory of Daniel Engel (University of Virginia) for providing the pCAGGS-enp-FLAG plasmid. We thank William Russell at the University of Texas Medical Branch (UTMB) Proteomics Core Facility for mass spectrometry analysis.

M.A.G.-B. and S.S.B. acknowledge start-up funds from the University of Texas Medical Branch.

J.F., M.A.G.-B., A.B., and S.S.B. conceived and designed the study. J.F., C.P., P.R., R.I.S., P.A.I., and S.S.B. contributed to the methodology and investigation. J.F. and S.S.B. wrote the first draft. J.F., C.P., P.A.I., M.A.G.-B., A.B., and S.S.B. reviewed and edited the article. M.A.G.-B., A.B., and S.S.B. acquired funding and resources and supervised the study.

REFERENCES

1. Burd EM. 2015. Ebola virus: a clear and present danger. J Clin Microbiol 53:4–8. https://doi.org/10.1128/JCM.03115-14.
2. Baize S, Pannetier D, Oestreicher L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sov M, Keita S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolli M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouna B, Diallo AK, Formenty P, Van Herp M, Günther S. 2014. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371:1418–1425. https://doi.org/10.1056/NEJMoa1404505.
3. Centers for Disease Control and Prevention. 2017. 2014–2016 Ebola outbreak in West Africa. Centers for Disease Control and Prevention, Atlanta, GA.
4. Gostin LO. 2018. New Ebola outbreak in Africa is a major test for the WHO. JAMA 320:125. https://doi.org/10.1001/jama.2018.8537.
5. Feldmann H, Geisbert TW. 2011. Ebola haemorrhagic fever. Lancet 377:849–862. https://doi.org/10.1016/S0140-6736(10)60667-8.
6. Bukreyev AA, Chandran K, Dolnik O, Dye JM, Ebihara H, Leroy EM, Mühlberger E, Netesov SV, Patterson JL, Pawaeska JT, Saphire EO, Smither SJ, Takada A, Towner JS, Volchkov VE, Warren TK, Kuhn JH. 2014. Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol 159:821–830. https://doi.org/10.1007/s00705-013-1846-9.
7. Martin B, Canard B, Decroly E. 2017. Filovirus proteins for antiviral drug discovery: structure/function bases of the replication cycle. Antiviral Res 141:48–61. https://doi.org/10.1016/j.antiviral.2017.02.004.
8. Elliott LH, Kiley MP, McCormick JB. 1985. Descriptive analysis of Ebola outbreak in Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol 159:821–830. https://doi.org/10.1007/s00705-013-1846-9.
9. Martin B, Canard B, Decroly E. 2017. Filovirus proteins for antiviral drug discovery: structure/function bases of the replication cycle. Antiviral Res 141:48–61. https://doi.org/10.1016/j.antiviral.2017.02.004.
10. Mühlberger E. 2007. Filovirus replication and transcription. Future Virol 2:205–215. https://doi.org/10.2217/17460794.2.2.205.
11. Ortín J, Martin-Benito J. 2015. The RNA synthesis machinery of negative-stranded RNA viruses. Virology 479-480:532–544. https://doi.org/10.1016/j.virol.2015.03.018.
12. Kuhn JH. 2008. Molecular characteristics of filoviruses, p 175–264. In Filoviruses: a compendium of 40 years of epidemiological, clinical, and laboratory studies. Springer-Verlag, Vienna, Austria.
13. Mühlberger E, Weik M, Volchkov VE, Klenk H-D, Becker S. 1999. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J Virol 73:2333–2342.
14. Volchkov VE, Volchkova VA, Chepurnov AA, Blinov VM, Dolnik O, Netesov SV, Feldmann H. 1999. Characterization of the L gene and 5′ trailer region of Ebola virus. J Gen Virol 80:355–362. https://doi.org/10.1099/0022-1317-80-2-355.
15. Enterlein S, Schmidt KM, Schumann M, Conrad D, Krahleng V, Olejnik J, Mühlberger E. 2009. The Marburg virus 3′ noncoding region structurally and functionally differs from that of Ebola virus. J Virol 83:4508–4519. https://doi.org/10.1128/JVI.02429-08.
16. Sanchez A, Kiley MP, Holloway BP, Auperin DD. 1993. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 29:141–161. https://doi.org/10.1016/0168-1702(93)90063-5.
17. Enterlein S, Schmidt KM, Schumann M, Conrad D, Krahleng V, Olejnik J, Mühlberger E. 2009. The Marburg virus 3′ noncoding region structurally and functionally differs from that of Ebola virus. J Virol 83:4508–4519. https://doi.org/10.1128/JVI.02429-08.
18. Sanchez A, Kiley MP, Holloway BP, Auperin DD. 1993. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 29:141–161. https://doi.org/10.1016/0168-1702(93)90063-5.
19. Weik M, Enterlein S, Schlenz K, Mühlberger E. 2005. The Ebola virus genomic replication promoter is bipartite and follows the rule of six. J Virol 79:10660–10671. https://doi.org/10.1128/JVI.79.16.10660-10671 .
20. Weik M, Modrof J, Klenk H, Mühlberger E, Becker S, Mu E. 2002. Ebola virus VP30-mediated transcription is regulated by RNA secondary struc-
turo formation. Virolology 76:8532–8539. https://doi.org/10.1128/JVI.76.17.8532-8539.2002.

19. Ilinsky PA, Tigabu B, Ivanov A, Ammosova T, Obukhov Y, Garron T, Kumari N, Kovalskyy D, Platonov MO, Naumchik VS, Freiberg AN, Nekhai S, Bukreyev A. 2014. Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. J Biol Chem 289:22723–22738. https://doi.org/10.1074/jbc.M114.575050.

20. Biedenkopf N, Hartlieb B, Hoenen T, Becker S. 2013. Phosphorylation of ebola virus VP30 influences the composition of the viral nucleocapsid complex: impact on viral transcription and replication. J Biol Chem 288:11165–11174. https://doi.org/10.1074/jbc.M113.461285.

21. Kruse T, Biedenkopf N, Hertz EPT, Dietzel E, Stalmann G, López-Méndez B, Davey NE, Nilsson J, Becker S. 2018. The Ebola virus nucleoprotein recruits the host PP2A-B56 phosphatase to activate transcriptional support activity of VP30. Mol Cell 69:136–145.e6. https://doi.org/10.1016/j.molcel.2017.11.034.

22. Sztuba-Solinska J, Diaz L, Kumar MR, Kolb G, Wiley MR, Joziwick L, Kuhn JH, Palacios G, Radhakrishny SR, Le Grice SFJ, Johnson P. 2016. A small stem-loop structure of the Ebola virus trailer is essential for replication and interacts with heat-shock protein A8. Nucleic Acids Res 44:9831–9846. https://doi.org/10.1093/nar/gkw825.

23. Cortes JM, Towner JS, Honig JE, Shoemaker TR, Nichol ST. 2003. Analysis of the role of predicted RNA secondary structures in Ebola virus replication. Virolology 306:210–218. https://doi.org/10.1006/viro.2002.042202(2002)0014-4.

24. Romero-Brey I, Bartenschlager R. 2014. Membranous replication factories induced by plus-strand RNA viruses. Viruses 6:2826–2857. https://doi.org/10.3390/v6072826.

25. Kopek BG, Perkins G, Miller DJ, Ellisman MH, Ahlquist P. 2007. Three-dimensional architecture of DENV-2 nucleocapsid: the viral RNA is folded into two distinct stem-loop domains. J Biol Chem 282:11011–11020. https://doi.org/10.1074/jbc.M106.575206.

26. Hoenen T, Shabman RS, Groseth A, Hekker A, Weber M, Schudt G, Dolnikova L, Kawaoka Y. 2011. The importance of the role of predicted RNA secondary structures in Ebola virus replication. J Virol 86:11779–11788. https://doi.org/10.1128/JVI.01525-12.

27. Hoenen T, Shabman RS, Groseth A, Hekker A, Weber M, Schudt G, Dolnikova L, Kawaoka Y. 2011. The importance of the role of predicted RNA secondary structures in Ebola virus replication. J Virol 86:11779–11788. https://doi.org/10.1128/JVI.01525-12.

28. Nanbo A, Watanabe S, Halfmann P, Kawaoka Y. 2013. The spatio-temporal distribution of Ebola virus proteins and RNA in infected cells. J Virol 87:6120–6130. https://doi.org/10.1128/JVI.00949-13.

29. Olejnik J, Ryabchikova E, Corley RB, Muhleberger E. 2011. Intracellular events and cell fate in fowl pox virus. Viruses 3:1501–1531. https://doi.org/10.3390/v3081501.

30. Nelson EV, Schmidt KM, Defulbre LD, Doganyan S, Banayda Y, Olejnik J, Hume AJ, Ryabchikova E, Ebihara H, Kedesha N, Ha T, Muhleberger E. 2016. Ebola virus does not induce stress granule formation during infection and sequesters stress granule proteins within viral inclusions. J Virol 90:7268–7284. https://doi.org/10.1128/JVI.00459-16.

31. Hartmuth K, Vornlocher H-P, Lührmann R. 2004. Tobramycin affinity tag purification of spliceosomes. Mol Cell Biol 24:757–46. https://doi.org/10.1128/MCB.14.5.759-750.547.

32. Manokaran G, Finol E, Wang C, Gunaratne J, Bahl J, Ong EZ, Tan HC, Sessions OM, Ward AM, Gubler DJ, Harris E, Garcia-Blanco MA, Ooi EE. 2015. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science 350:217–221. https://doi.org/10.1126/science.aab3369.

33. Ward AM, Calvert ME, Wear LD, Kang S, Levitt B, Dimopoulos G, Noda T, Kolesnikova L, Becker S, Feldmann H, Kawaoka Y. 2011. Identification of Staufen in the human microsomal STAU1 protein interacts with influenza virus ribonucleoproteins and is required for efficient virus multiplication. J Virol 85:6630–6641. https://doi.org/10.1128/JVI.05249-10.

34. Chatel-Chaix L, Clément J, Bériaud V, Garnot A, Mouland AJ, Cle J, Martel C, Desgroseillers L. 2004. Identification of Staufen in the human immunodeficiency virus type 1 Gag ribonucleoprotein complex and a role in generating infectious viral particles. Mol Cell Biol 24:2637–2648. https://doi.org/10.1128/MCB.24.7.2637-2648.2004.

35. Tchesnokov EP, Raesimikian P, Ngure M, Marchant D, Götze M. 2018. A recombinant RNA-dependent RNA polymerase complex of Ebola virus. Sci Rep 8:3970. https://doi.org/10.1038/s41598-018-22328-3.

36. Wickham L, DuChaine T, Luo M, Nabi IR, DesGroseillers L. 1999. Malamian Staus is a double-stranded-RNA- and tubulin-binding protein which localizes to the rough endoplasmic reticulum. Mol Cell Biol 19:2220–2230. https://doi.org/10.1128/MCB.19.3.2220.

37. Noda T, Kolesnikova L, Becker S, Kawaoka Y. 2011. The importance of the Np/vp15 ratio in Ebola virus nucleocapsid formation. J Infect Dis 204:5878–5876. https://doi.org/10.1093/infdis/jir130.

38. Le Sage V, Cinti A, McCarthy S, Amorim R, Rao S, Daino GL, Tramontano E, Branch DR, Mouland AJ. 2017. Ebola virus VP35 blocks stress granule assembly. Virology 502:73–83. https://doi.org/10.1016/j.virol.2016.12.012.

39. Feng Z, Ceveny M, Yan Z, He B. 2007. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol 81:182–192. https://doi.org/10.1128/JVI.01006-06.
Role of Staufen1 in Ebola Virus Infection

54. Schumann M, Gantke T, Muhlberger E. 2009. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol 83:8993–8997. https://doi.org/10.1128/JVI.00523-09.

55. Modrof J, Muhlberger E, Klenk HD, Becker S. 2002. Phosphorylation of VP30 impairs Ebola virus transcription. J Biol Chem 277:33099–33104. https://doi.org/10.1074/jbc.M203775200.

56. Kirchdoerfer RN, Moyer CL, Abelson DM, Saphire EO. 2016. The Ebola virus VP30-NP interaction is a regulator of viral RNA synthesis. PloS Pathog 12:e1005937. https://doi.org/10.1371/journal.ppat.1005937.

57. Groseth A, Charton JE, Sauermann M, Feldmann F, Jones SM, Hoenen T, Feldmann H. 2009. The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified. Virus Res 140:8–14. https://doi.org/10.1016/j.virres.2008.10.017.

58. Iwasa A, Halfmann P, Noda T, Oyama M, Kozuka-Hata H, Watanabe S, Shimojima M, Watanabe T, Kawaoka Y. 2011. Contribution of sec61α to the life cycle of Ebola virus. J Infect Dis 204:S919–S926. https://doi.org/10.1086/654093.

59. Luthra P, Jordan DS, Leung DW, Amarasinghe GK, Basler CF. 2015. Ebola virus VP35 interaction with dynein LC8 regulates viral RNA synthesis. J Virol 89:5148–5153. https://doi.org/10.1128/JVI.03652-14.

60. Takahashi K, Halfmann P, Oyama M, Kozuka-Hata H, Noda T, Kawaoka Y. 2013. DNA topoisomerase 1 facilitates the transcription and replication of the Ebola virus genome. J Virol 87:8862–8869. https://doi.org/10.1128/JVI.03544-12.

61. Luo M, Duchaine TF, DesGroseillers L. 2002. Molecular mapping of the determinants involved in human Staufen–ribosome association. Biochem J 365:817–824. https://doi.org/10.1042/bj20020263.

62. García-Dorival I, Wu W, Armstrong SD, Barr JN, Carroll MW, Hewson R, Hiscox JA. 2016. Elucidation of the cellular interactome of Ebola virus. Annu Rev Virol 120:195–208. https://doi.org/10.1016/j.cell.2004.11.050.

63. Park E, Maquat LE. 2013. Staufen-mediated mRNA decay. Wiley Interdiscip Rev RNA 4:423–435. https://doi.org/10.1002/wrna.1168.

64. Luo M, Duchaîne TF, DesGroseillers L. 2002. Molecular mapping of the determinants involved in human Staufen–ribosome association. Biochem J 365:817–824. https://doi.org/10.1042/bj20020263.

65. Shabman RS, Leung DW, Johnson J, Glennon N, Gulcicek EE, Stone KL, Leung L, Hensley L, Amarasinghe GK, Basler CF. 2011. DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function. J Infect Dis 204:S911–S918. https://doi.org/10.1093/infdis/jir343.

66. Thomas MG, Tosar LJ, Desbats MA, Leishman CC, Boccaccio GL. 2009. Mammalian Staufen 1 is recruited to stress granules and impairs their assembly. J Cell Sci 122:563–573. https://doi.org/10.1242/jcs.038208.

67. Kim YK, Furic L, DesGroseillers L, Maquat LE. 2005. Mammalian Staufen1 recruits Upf1 to specific mRNA 3′UTRs so as to elicit mRNA decay. Cell 120:195–208. https://doi.org/10.1016/j.cell.2004.11.050.

68. Park E, Maquat LE. 2013. Staufen-mediated mRNA decay. Wiley Interdiscip Rev RNA 4:423–435. https://doi.org/10.1002/wrna.1168.

69. Whelan SP, Barr JN, Wertz GW. 2004. Transcription and replication of nonsegmented negative strand RNA viruses. Curr Top Microbiol Immunol 283:61–119.

70. Hoenen T, Groseth A, Clarke M, Koehler A, Noda T, Becker S, Briggs JAG. 2017. Structure and assembly of the Ebola virus nucleocapsid. Nature 551:394–397. https://doi.org/10.1038/nature24490.

71. Hoenen T, Groseth A, de Kok-Mercado F, Kuhn JH, Wahl-Jensen V. 2011. Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res 91:195–208. https://doi.org/10.1016/j.antiviral.2011.06.003.

72. Dalet A, Gatti E, Pierre P. 2016. Dynamic phosphorylation of VP30 impairs Ebola virus transcription. J Biol Chem 277:33099–33104. https://doi.org/10.1074/jbc.M203775200.

73. Liu Y, Sune C, Garcia-Blanco MA. 1999. Human immunodeficiency virus type 1 Tat-dependent activation of an arrested RNA polymerase II elongation complex. Virology 255:337–346. https://doi.org/10.1006/viro.1998.9585.

74. Yoon C-H, Kim S-Y, Byeon SE, Jeong Y, Lee J, Kim KP, Park J, Bae Y-S. 2015. p53-derived host restriction of HIV-1 replication by protein kinase R-mediated Tat phosphorylation and inactivation. J Virol 89:4262–4280. https://doi.org/10.1128/JVI.03087-14.

75. Dalet A, Gatti E, Pierre P. 2015. Integration of PKR-dependent translation inhibition with innate immunity is required for a coordinated anti-viral response. FEBs Lett 589:1539–1545. https://doi.org/10.1016/j.febslet.2015.05.006.

76. Lier C, Becker S, Biedenkopf N. 2016. Dynamic phosphorylation of Ebola virus VP30-L interaction identified. Virus Res 140:8–14. https://doi.org/10.1016/j.virusres.2011.08.003.

77. Ward AM, Gunaratne J, Garcia-Blanco MA. 2014. Identification of dengue virus VP30 in NP-induced inclusion bodies. Virology 512:39–47. https://doi.org/10.1016/j.virol.2017.09.006.

78. Park E, Maquat LE. 2013. Staufen-mediated mRNA decay. Wiley Interdiscip Rev RNA 4:423–435. https://doi.org/10.1002/wrna.1168.

79. Biedenkopf N, Lier C, Becker S. 2016. Dynamic phosphorylation of VP30 is essential for Ebola virus life cycle. J Virol 90:4914–4925. https://doi.org/10.1128/JVI.03257-15.

80. Ward AM, Gunaratne J, Garcia-Blanco MA. 2014. Identification of dengue virus VP30 in NP-induced inclusion bodies. Virology 512:39–47. https://doi.org/10.1016/j.virol.2017.09.006.

81. Ward AM, Gunaratne J, Garcia-Blanco MA. 2014. Identification of dengue virus VP30 in NP-induced inclusion bodies. Virology 512:39–47. https://doi.org/10.1016/j.virol.2017.09.006.